Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor.
biomarker
end-stage kidney disease
type 2 diabetes
Journal
Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
30
06
2020
revised:
03
10
2020
accepted:
27
10
2020
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Several circulating markers, including autoantibodies to erythropoietin receptor (anti-EPOR antibodies), have been identified as useful biomarkers in predicting diabetic kidney disease progression. However, a direct comparison of their utility is lacking. We aimed to validate and to compare the prognostic value of anti-EPOR antibodies with that of other known biomarkers, using the ADVANCE trial and its long-term follow-up, ADVANCE-ON, cohorts. In this nested case-control study from the ADVANCE trial cohort, we included 165 case participants who had the composite kidney outcome (renal replacement therapy, renal death, or doubling of serum creatinine to ≥200 μmol/l) and 330 matched controls. We compared the associations of baseline plasma levels of anti-EPOR antibodies, tumor necrosis factor receptor (TNFR)-1 and -2, and bone morphogenetic protein (BMP)-7 with kidney outcomes. Cases had higher baseline plasma levels of anti-EPOR antibodies than controls (median 1.7 vs. 0.6 enzyme-linked immunosorbent assay unit, Anti-EPOR antibodies provide a promising biomarker, as with TNFR1, TNFR2, and BMP-7, in predicting kidney disease progression in people with type 2 diabetes mellitus.
Identifiants
pubmed: 33615053
doi: 10.1016/j.ekir.2020.10.039
pii: S2468-0249(20)31710-1
pmc: PMC7879109
doi:
Types de publication
Journal Article
Langues
eng
Pagination
284-295Informations de copyright
© 2020 International Society of Nephrology. Published by Elsevier Inc.
Références
Clin Trials. 2017 Dec;14(6):629-638
pubmed: 28795578
Kidney Int. 2016 Dec;90(6):1211-1225
pubmed: 27591086
J Am Soc Nephrol. 2014 Sep;25(9):2003-15
pubmed: 24676641
Diabetes Care. 2018 Sep;41(9):1947-1954
pubmed: 29980527
Methods Mol Biol. 2019;1959:1-22
pubmed: 30852812
Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1343-52
pubmed: 27189318
Kidney Int. 2013 Sep;84(3):427-9
pubmed: 23989353
Nat Clin Pract Nephrol. 2007 Jan;3(1):20-30
pubmed: 17183259
J Am Soc Nephrol. 2006 Sep;17(9):2504-12
pubmed: 16899516
J Rheumatol. 2016 Jul;43(7):1328-34
pubmed: 27134248
Kidney Int. 2015 Feb;87(2):281-96
pubmed: 25140911
Diabetologia. 2001 Sep;44(9):1118-20
pubmed: 11596665
Diabetes Metab Res Rev. 2019 Nov;35(8):e3195
pubmed: 31207020
Kidney Int Rep. 2017 Sep 08;3(1):133-141
pubmed: 29340323
Diabetes Obes Metab. 2018 Oct;20 Suppl 3:14-18
pubmed: 30294954
Kidney Int. 2005 Apr;67(4):1483-8
pubmed: 15780101
Kidney Int. 2018 May;93(5):1198-1206
pubmed: 29398132
J Cell Physiol. 2011 Dec;226(12):3330-9
pubmed: 21321940
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1371-9
pubmed: 26175542
Kidney Int. 2013 Sep;84(3):468-81
pubmed: 23636173
Diabetes. 2007 Jul;56(7):1825-33
pubmed: 17456853
Kidney Int. 2013 Feb;83(2):278-84
pubmed: 23235570
J Am Soc Nephrol. 2017 Sep;28(9):2786-2793
pubmed: 28476763
Diabetes Care. 2016 May;39(5):694-700
pubmed: 27006512
Endocr J. 2018 Feb 26;65(2):181-191
pubmed: 29109360
Br J Haematol. 2013 Jan;160(2):244-50
pubmed: 23151030
Lancet. 2007 Sep 8;370(9590):829-40
pubmed: 17765963
Kidney Int. 2017 Jul;92(1):258-266
pubmed: 28396115
Am J Physiol Renal Physiol. 2018 Apr 1;314(4):F501-F516
pubmed: 29187371
JAMA. 2016 Aug 9;316(6):602-10
pubmed: 27532915
Kidney Int. 2007 Aug;72(4):455-63
pubmed: 17457371
Nat Med. 2019 May;25(5):805-813
pubmed: 31011203
J Am Soc Nephrol. 2012 Mar;23(3):507-15
pubmed: 22266663
Am J Kidney Dis. 2018 Mar;71(3):423-435
pubmed: 29336855
J Am Soc Nephrol. 2019 Sep;30(9):1746-1755
pubmed: 31292199
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916
N Engl J Med. 2014 Oct 9;371(15):1392-406
pubmed: 25234206